Identification of patients with ovarian cancer who are experiencing the highest benefit from bevacizumab in first-line setting based on their tumor intrinsic chemosensitivity (KELIM): GOG-0218 validation study.
Year: 2022
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Benoit You, Christopher Purdy, Elizabeth M. Swisher, Michael A. Bookman, Gini F. Fleming, Robert L. Coleman, Leslie M. Randall, Krishnansu Sujata Tewari, Bradley J. Monk, Robert S. Mannel, Joan L. Walker, Fabio Cappuccini, Larry J. Copeland, Mahvish Muzaffar, David Gardner Mutch, Andrea Elisabeth Wahner Hendrickson, Lainie P. Martin, Olivier Colomban, Robert Allen Burger
Institutions: Hospices Civils de Lyon, NRG Oncology, University of Washington, University of Arizona, University of Chicago, The US Oncology Network, Virginia Commonwealth University, University of California, Irvine, Creighton University, OU Health Stephenson Cancer Center, University of Oklahoma Health Sciences Center, University of California, Irvine Medical Center, The Ohio State University Wexner Medical Center, Vidant Medical Center, East Carolina University, Washington University in St. Louis, Mayo Clinic, Abramson Cancer Center, University of Pennsylvania, Lyon 1 Université, Centre pour l'innovation en cancérologie de Lyon
Language: English
Subfield: Reproductive Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4281697296